PriceTargets.com logo

NASDAQ:THTX - Theratechnologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.13
  • Forecasted Upside: 126.91 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.14 As of 03/5/2021 01:00 AM ET
▲ +0.01 (0.32%)
1 month | 3 months | 12 months
Get New Theratechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for THTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for THTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$7.13
▲ +126.91% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Theratechnologies in the last 3 months. The average price target is $7.13, with a high forecast of $11.00 and a low forecast of $2.00. The average price target represents a 126.91% upside from the last price of $3.14.
Buy
The current consensus among 5 polled investment analysts is to buy stock in Theratechnologies.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/13/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/12/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/11/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/9/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/7/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/6/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/4/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/6/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/26/2021Leede Jones GabDowngradeSpeculative Buy ➝ HoldLow
i
Rating by D. Loe at Leede Jones Gab
1/31/2021Royal Bank of CanadaReiterated RatingHold$2.00Low
i
10/16/2020MackieReiterated RatingBuy$4.50High
i
7/20/2020Royal Bank of CanadaReiterated RatingHold$2.00Low
i
7/13/2020Canaccord GenuityReiterated RatingBuyLow
i
7/8/2020Echelon Wealth PartnersReiterated RatingBuy$11.00High
i
6/24/2020Canaccord GenuityReiterated RatingBuy$11.00Low
i
4/15/2020Canaccord GenuityLower Price TargetBuy$12.00 ➝ $11.00Medium
i
3/3/2020Canaccord GenuityReiterated RatingBuy$95.50High
i
2/26/2020Canaccord GenuityUpgradeBuyLow
i
2/25/2020MackieReiterated RatingBuy$5.80Low
i
Rating by Andre Uddin at Mackie
12/11/2019MackieUpgradeHold ➝ BuyLow
i
12/2/2019Canaccord GenuityInitiated CoverageBuyHigh
i
(Data available from 3/6/2016 forward)
Theratechnologies logo
Theratechnologies Inc., a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. It offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. The company's pipeline products include F8 Formulation that could be used for the treatment of HIV-associated lipodystrophy; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was founded in 1993 and is headquartered in Montreal, Canada.
Read More

Today's Range

Now: $3.14
$2.92
$3.18

50 Day Range

MA: $2.68
$2.20
$3.51

52 Week Range

Now: $3.14
$1.33
$3.57

Volume

331,941 shs

Average Volume

820,312 shs

Market Capitalization

$294.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Theratechnologies?

The following Wall Street analysts have issued stock ratings on Theratechnologies in the last twelve months: Canaccord Genuity, Echelon Wealth Partners, Leede Jones Gab, Mackie, Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for THTX.

What is the current price target for Theratechnologies?

4 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. Their average twelve-month price target is $7.13, suggesting a possible upside of 126.9%. Canaccord Genuity has the highest price target set, predicting THTX will reach $11.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $2.00 for Theratechnologies in the next year.
View the latest price targets for THTX.

What is the current consensus analyst rating for Theratechnologies?

Theratechnologies currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe THTX will outperform the market and that investors should add to their positions of Theratechnologies.
View the latest ratings for THTX.

What other companies compete with Theratechnologies?

Other companies that are similar to Theratechnologies include Innoviva, Zogenix, Omeros, Arcturus Therapeutics, Northwest Biotherapeutics, Pliant Therapeutics, Protagonist Therapeutics, Cassava Sciences, Aclaris Therapeutics, BioXcel Therapeutics, Akero Therapeutics, Enanta Pharmaceuticals, Trillium Therapeutics, Avid Bioservices and Radius Health.

How do I contact Theratechnologies' investor relations team?

Theratechnologies' physical mailing address is 2015 Peel Street 5th Floor, MONTREAL A8, H3A 1T8. The company's listed phone number is 514-336-7800 and its investor relations email address is [email protected] The official website for Theratechnologies is www.theratech.com.